- In August 2022, QIAGEN announced the publication of a validation study for its clinical decision support software, QIAGEN Clinical Insight Interpret One (QCI Interpret One), in the Journal of Molecular Pathology. The study, independently conducted by Genomics Quality Assessment (GenQA) and commissioned by QIAGEN, demonstrated that QCI Interpret One exhibited superior concordance with expert panels in variant classification for oncology patient samples when compared to human reviewers. Its contribution in global transplant diagnostics market by facilitating precise and efficient decision support tools which are crucial for optimizing patient care and enhancing diagnostic accuracy
- In March 2022, Immucor, Inc. expanded its transplant diagnostics portfolio with the introduction of two new offerings, further reinforcing its commitment to advancing histocompatibility in transfusion and transplantation diagnostics. This strategic expansion holds significant relevance to the global Transplant Diagnostics Market, where the need for advanced diagnostic tools is critical to improving transplant success rates and patient outcomes
- In March 2022, Biocartis and Ophiomics announced a strategic collaboration to commercialize HepatoPredict, a prognostic gene expression signature test developed to identify liver transplant recipients most likely to benefit from the procedure. This partnership leverages Biocartis' expertise in commercialization alongside Ophiomics' pioneering research in liver disease diagnostics, with the goal of enhancing patient outcomes and optimizing decision-making in liver transplantation. This collaboration holds significant relevance to the global Transplant Diagnostics Market, where the demand for precise diagnostic tools is growing. HepatoPredict represents a key advancement in personalized medicine, offering clinicians a valuable tool to improve transplant success rates and better tailor treatments to individual patients
- In January 2022, Hoffmann-La Roche Ltd. introduced Cobas Infinity Edge, a cloud-based point-of-care platform designed for global accessibility. This innovative solution equips healthcare practitioners with advanced technology to effectively manage patient data, streamline clinical workflows, and facilitate seamless connectivity across healthcare systems worldwide. The introduction of Cobas Infinity Edge provide real-time access to patient data and enhanced connectivity are crucial for improving transplant outcomes
- In May 2024, Thermo Fisher introduced the CXCL10 testing service, specifically designed for kidney transplant patients. This advanced service enables faster detection of the CXCL10 chemokine compared to existing testing methods, offering enhanced diagnostic efficiency. The launch of the CXCL10 testing service is highly relevant for timely and accurate monitoring of transplant rejection and critical for improving patient outcomes
